Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes
Mood, Memory Deficit
About this trial
This is an interventional treatment trial for Mood focused on measuring Corticosteroids, Riluzole, Memantine, Memory
Eligibility Criteria
Inclusion Criteria: 18-70 years old English speaking Able to provide informed consent Scheduled to receive a corticosteroid burst of at least 20 mg prednisone or equivalent for at least 7 days Exclusion Criteria: History of allergic reaction to memantine and/or riluzole Pregnant or nursing women History of liver disease, myocardial infarction, renal failure, diabetes with poor glycemic control, or other unstable medical condition Mental retardation, dementia, or other severe cognitive disorder Prior prednisone therapy in the last 14 days Current alcohol/substance abuse/dependence
Sites / Locations
- UT Southwestern
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Placebo Comparator
Active Comparator
Memantine
Placebo
Riluzole
Memantine is used to determine if patients given pretreatment to corticosteroid therapy for inflammatory illnesses will show lesser declarative memory impairment than those receiving placebo. Baseline 10mg x 3 days, then 10mg BID x 4 days.
Inactive ingredient matching the active medication in appearance
Riluzole is given to patients receiving corticosteroid therapy for inflammatory illnesses pretreatment to determine if they show lesser declarative memory impairment than those receiving placebo. Baseline 50mg x 3 days, then 50mg BID x 4 days.